Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as
we learn more about the individual genetic variations that contribute to the drugs' efficacy …

Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances,
primarily using the genome-wide association study approach, are transforming what we …

There is considerable interindividual variability in the response to antiplatelet and
anticoagulant therapies, and this variation may be attributable to genetic variants. There has …

Genetic variations have been shown to influence drug metabolism, risk of adverse drug
events, and pharmacodynamic responses for many drugs routinely used to treat patients …

Pharmacogenetics has offered compelling evidence toward the individualization of
clopidogrel and warfarin therapies. The rapid advances in technology make the clinical …

Genetics has given a real boost to personalized and precision medicine, providing data
used either for precise diagnostics, prediction of the course of illness, or for selecting therapy …

Background Early neurological deterioration (END) is common in acute ischemic stroke (IS).
However, the underlying mechanisms for END are unclear. The aim of this study was to …

Objective: Clopidogrel is a clinically important oral antiplatelet agent for the treatment or
prevention of cerebrovascular disease. However, different individuals have different …

Clopidogrel is one of the most commonly prescribed medications worldwide. Recent
advisories from the US Food and Drug Administration have drawn attention to the possibility …

Clopidogrel efficacy is influenced by genetic variation of cytochrome P450 (CYP) 2C19,
however, few studies have considered patients who have a stroke. We used electronic …